Erythrocyte-binding therapeutics

Patent metadata

Field	Value
Publication number	US-9517257-B2
Application number	US-201213397202-A
Country	US
Kind code	B2
Filing date	Feb 15, 2012
Priority date	Aug 10, 2010
Publication date	Dec 13, 2016
Grant date	Dec 13, 2016

Abstract

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

First claim

The invention claimed is:

1. A pharmaceutically acceptable composition for inducing tolerance of an antigenic therapeutic protein comprising:
a fusion molecule having an erythrocyte-binding moiety and a portion of the antigenic therapeutic protein,
wherein said erythrocyte-binding moiety has the ability to non-covalently, specifically bind an exterior erythrocyte surface in situ in blood and
wherein said antigenic therapeutic protein portion is a portion of human Factor VIII.

2. The composition of claim 1 wherein the erythrocyte-binding moiety specifically binds to a biomolecule chosen from the group consisting of Band 3 (CD233), aquaporin-1, Glut-1, Kidd antigen, RhAg/Rh50 (CD241), Rh (CD240), Rh30CE (CD240CE), Rh30D (CD240D), Kx, glycophorin A, glycophorin B (CD235b), glycophorin C (CD235c), glycophorin D (CD235d), Kell (CD238), Duffy/DARCi (CD234), CR1 (CD35), DAF (CD55), Globoside, CD44, ICAM-4 (CD242), Lu/B-CAM (CD239), XG1/XG2 (CD99), EMMPRIN/neurothelin (CD147), JMH, Glycosyltransferase, Cartwright, Dombrock, C4A/CAB, Scianna, MER2, stomatin, BA-1 (CD24), GPIV (CD36), CD108, CD139, and H antigen (CD173).

3. The composition of claim 1 wherein the erythrocyte-binding moiety is chosen from the group consisting of a peptide ligand, an antibody, an antibody fragment, and a single chain variable fragment (ScFv).

4. The composition of claim 1 wherein the erythrocyte-binding moiety comprises an antibody, an antibody fragment or an ScFv derived from a hybridoma that produces an antibody against an erythrocyte, with the hybridoma being chosen from the group consisting of BRIC 4, BRIC 5, BRIC 6, BRIC 10, BRIC 14, BRIC 18, BRIC 39, BRIC 66, BRIC 68, BRIC 69, BRIC 87, BRIC 108, BRIC 110, BRIC 111, BRIC 125, BRIC 126, BRIC 128, BRIC 145, BRIC 155, BRIC 157, BRIC 163, BRIC 170, BRIC 198, BRIC 203, BRIC 216, BRIC 220, BRIC 221, BRIC 222, BRIC 229, BRIC 230, BRIC 231, BRIC 235, BRIC 256, BRAC 17, BRAC 18, BGRL 1, BGRL 2, BGRL 11, BGRL 100, BRAD 3, BIRMA D6, BIRMA D10, BIRMA K3, BIRMA K3, BIRMA 84B; 6A7; COE; and KZ1.

5. A method of inducing immunotolerance, the method comprising administering the composition of claim 1 to a patient.

6. The method of claim 5 wherein the erythrocyte-binding moiety specifically binds to a biomolecule chosen from the group consisting of Band 3 (CD233), aquaporin-1, Glut-1, Kidd antigen, RhAg/Rh50 (CD241), Rh (CD240), Rh30CE (CD240CE), Rh30D (CD240D), Kx, glycophorin A, glycophorin B (CD235b), glycophorin C (CD235c), glycophorin D (CD235d), Kell (CD238), Duffy/DARCi (CD234), CR1 (CD35), DAF (CD55), Globoside, CD44, ICAM-4 (CD242), Lu/B-CAM (CD239), XG1/XG2 (CD99), EMMPRIN/neurothelin (CD147), JMH, Glycosyltransferase, Cartwright, Dombrock, C4A/CAB, Scianna, MER2, stomatin, BA-1 (CD24), GPIV (CD36), CD108, CD139, and H antigen (CD173).

7. The method of claim 5 wherein the erythrocyte-binding moiety is chosen from the group consisting of a peptide ligand, an antibody, an antibody fragment, and a single chain variable fragment (ScFv).

8. The method of claim 5 wherein the erythrocyte-binding moiety comprises an antibody, an antibody fragment or an ScFv derived from a hybridoma that produces an antibody against an erythrocyte, with the hybridoma being chosen from the group consisting of BRIC 4, BRIC 5, BRIC 6, BRIC 10, BRIC 14, BRIC 18, BRIC 39, BRIC 66, BRIC 68, BRIC 69, BRIC 87, BRIC 108, BRIC 110, BRIC 111, BRIC 125, BRIC 126, BRIC 128, BRIC 145, BRIC 155, BRIC 157, BRIC 163, BRIC 170, BRIC 198, BRIC 203, BRIC 216, BRIC 220, BRIC 221, BRIC 222, BRIC 229, BRIC 230, BRIC 231, BRIC 235, BRIC 256, BRAC 17, BRAC 18, BGRL 1, BGRL 2, BGRL 11, BGRL 100, BRAD 3, BIRMA D6, BIRMA D10, BIRMA K3, BIRMA K3, BIRMA 84B; 6A7; COE; and KZ1.

9. The composition of claim 1 wherein said erythrocyte-binding moiety comprises an antibody, antibody fragment or scFv derived from a 10F7 clone.

10. A pharmaceutically acceptable composition for inducing tolerance to a therapeutic protein in a subject having a deficiency in production of a functional native protein, comprising:
a fusion molecule comprising an erythrocyte-binding moiety and a portion of the antigenic therapeutic protein,
wherein said erythrocyte-binding moiety has the ability to non-covalently, bind an exterior surface of erythrocytes in situ in blood and does not specifically bind to other blood components,
wherein said therapeutic protein is Factor VIII, and wherein the antigenic portion consists of a portion of human Factor VIII.

11. The composition of claim 10 , wherein the erythrocyte-binding moiety is chosen from the group consisting of a peptide ligand, an antibody, an antibody fragment, and a single chain variable fragment (ScFv).

12. The composition of claim 10 , wherein the erythrocyte-binding moiety comprises an antibody, an antibody fragment or an ScFv derived from a hybridoma that produces an antibody against an erythrocyte, with the hybridoma being chosen from the group consisting of BRIC 4, BRIC 5, BRIC 6, BRIC 10, BRIC 14, BRIC 18, BRIC 39, BRIC 66, BRIC 68, BRIC 69, BRIC 87, BRIC 108, BRIC 110, BRIC 111, BRIC 125, BRIC 126, BRIC 128, BRIC 145, BRIC 155, BRIC 157, BRIC 163, BRIC 170, BRIC 198, BRIC 203, BRIC 216, BRIC 220, BRIC 221, BRIC 222, BRIC 229, BRIC 230, BRIC 231, BRIC 235, BRIC 256, BRAC 17, BRAC 18, BGRL 1, BGRL 2, BGRL 11, BGRL 100, BRAD 3, BIRMA D6, BIRMA D10, BIRMA K3, BIRMA K3, BIRMA 84B; 6A7; COE; and KZ1.

13. The composition of claim 10 , wherein said erythrocyte-binding moiety comprises an single chain variable fragment (ScFv) derived from a 10F7 clone.

14. A pharmaceutically acceptable composition for inducing tolerance to a therapeutic protein in a subject having a deficiency in production of a functional native protein, comprising:
a fusion molecule comprising an erythrocyte-binding moiety and an antigenic portion of the therapeutic protein,
wherein said erythrocyte-binding moiety has the ability to non-covalently, bind an exterior surface of erythrocytes in situ in blood and does not specifically bind to other blood components,
wherein the erythrocyte-binding moiety is a single-chain variable fragment (scFv) derived from 10F7 that targets glycophorin A on erythrocytes, wherein said therapeutic protein is Factor VIII, and wherein the antigenic portion of the Factor VIII comprises a portion of human Factor VIII.

15. The composition of claim 14 , wherein the erythrocyte-binding moiety is fused to the antigenic portion of the therapeutic protein.

16. The composition of claim 14 , wherein the erythrocyte-binding moiety is fused to the N- or C-terminus of the antigenic portion of the therapeutic protein.

Assignees

• Hubbell Jeffrey A
• Kontos Stéphane
• Dane Karen Y
• Ecole Polytechnique Fed De Lausanne (Epfl)

Inventors

• Hubbell Jeffrey A
• Kontos Stéphane
• Dane Karen Y

Classifications

• C12N9/82

  Asparaginase {(3.5.1.1)} · CPC title

• C07K2319/43

  containing a FLAG-tag · CPC title

• A61K2039/6031

  Proteins · CPC title

• C07K2319/41

  containing a Myc-tag · CPC title

• C07K14/62

  Insulins · CPC title